9/19/2025

This is our weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read the latest in the article series here.

Source: SeekingAlpha

9/18/2025

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Danaher Corporation is one of them. Danaher Corporation (NYSE:DHR), a global leader in life sciences and diagnostics, continues to advance its bioprocessing, diagnostics, and life sciences segments through innovation and strategic partnerships. In Q2 2025, […]

Source: Yahoo

9/18/2025

Consumers Energy today announced Shannon Thomas as the company's senior vice president and chief people officer, effective September 29.

Source: Yahoo

9/16/2025

DHR's Life Sciences unit faces revenue declines from weak demand, but new products and biotech advances offer growth potential.

Source: Yahoo

9/15/2025

HOLX's Breast Health revival, fueled by AI, leadership shifts and product upgrades, is setting up a growth rebound.

Source: Yahoo

9/15/2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Danaher (NYSE:DHR) and the rest of the research tools & consumables stocks fared in Q2.

Source: Yahoo

9/12/2025

Danaher Corp. stock underperforms Friday when compared to competitors

Source: MarketWatch

9/11/2025

DHR's Biotechnology unit grows 6% in Q2, driven by bioprocessing, despite weakness in research equipment demand.

Source: Yahoo

9/11/2025

Danaher Corp. stock underperforms Thursday when compared to competitors despite daily gains

Source: MarketWatch

9/10/2025

Beckman Coulter Diagnostics, a Danaher company and a leader in global clinical diagnostics innovation, today launched the industry's first fully automated Brain-derived Tau (BD-Tau) research use only (RUO) immunoassay test. Access BD-Tau, along with Beckman Coulter Diagnostics' expanding portfolio of neurodegenerative disease RUO assays, is available for use on the groundbreaking DxI 9000 Immunoassay Analyzer and Access 2 Analyzer. This portfolio of assays enables precision medicine research on

Source: Yahoo

9/10/2025

If you have been following Danaher (DHR) lately, you may have noticed that the stock’s performance has come under the microscope. While there is no single headline grabbing investor attention, the shares have been trending lower, prompting some to wonder if this slide is a warning sign or simply a possible opening for value-driven buyers. For shareholders, the current environment raises a familiar question: is this move noise, or does it signal something deeper happening at the company? Over...

Source: Yahoo

9/9/2025

Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on October 31, 2025 to holders of record on September 26, 2025.

Source: Yahoo

9/9/2025

Danaher Corp. stock underperforms Tuesday when compared to competitors

Source: MarketWatch

9/8/2025

Third Point's Q2 2025 13F portfolio rose to $7.62B, with increased concentration in top holdings. Read more about the portfolio here.

Source: SeekingAlpha

9/8/2025

The global Radioimmunoassay (RIA) market is set to expand from $710 million in 2024 to $1.12 billion by 2033, growing at a CAGR of 5.21%. Key drivers include advancements in endocrinology, oncology, infectious disease research, and wider application of RIA in both advanced and emerging markets. The market is propelled by technological improvements in RIA kits, increased demand for precise disease diagnosis, and growing pharmaceutical applications. However, it faces competition from non-radioacti

Source: Yahoo

9/8/2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently - over the past six months, the collective 1.4% gain for healthcare stocks has fallen short of the S&P 500’s 15.5% rise.

Source: Yahoo

9/7/2025

Danaher faces revenue pressure and rising leverage despite strong market exposure, making its high valuation harder to justify. Find out why DHR stock is a hold.

Source: SeekingAlpha

9/5/2025

A10 Networks Names Michelle Caron as Finance Chief

Source: MarketWatch

9/2/2025

DHR posts gains in bioprocessing, biotech and diagnostics, while life sciences softness and high debt weigh.

Source: Yahoo

9/1/2025

The PFAS Testing Companies Quadrant delivers a thorough analysis of the global PFAS Testing market, ranking the top 14 companies from over 100 evaluations. With a spotlight on key players like Agilent Technologies, Thermo Fisher Scientific, and Danaher Corporation, the report explores innovation, technological advancements, and market trends in PFAS detection and analysis. As rising global awareness on environmental contamination boosts market growth, the industry faces challenges like high capi

Source: Yahoo